CA3223859A1 - Salt and crystal forms of an epidermal growth factor receptor inhibitor - Google Patents

Salt and crystal forms of an epidermal growth factor receptor inhibitor Download PDF

Info

Publication number
CA3223859A1
CA3223859A1 CA3223859A CA3223859A CA3223859A1 CA 3223859 A1 CA3223859 A1 CA 3223859A1 CA 3223859 A CA3223859 A CA 3223859A CA 3223859 A CA3223859 A CA 3223859A CA 3223859 A1 CA3223859 A1 CA 3223859A1
Authority
CA
Canada
Prior art keywords
salt
compound
crystalline
egfr
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223859A
Other languages
English (en)
French (fr)
Inventor
Erika BUTLER
Caitlin N. Kinkema
Christopher Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CA3223859A1 publication Critical patent/CA3223859A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3223859A 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor Pending CA3223859A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214089P 2021-06-23 2021-06-23
US63/214,089 2021-06-23
PCT/US2022/034550 WO2022271846A1 (en) 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
CA3223859A1 true CA3223859A1 (en) 2022-12-29

Family

ID=82608408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223859A Pending CA3223859A1 (en) 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Country Status (9)

Country Link
US (1) US20240293404A1 (https=)
EP (1) EP4359400B1 (https=)
JP (1) JP2024523506A (https=)
CN (1) CN117836287A (https=)
CA (1) CA3223859A1 (https=)
ES (1) ES3042447T3 (https=)
IL (1) IL309469A (https=)
TW (1) TW202317543A (https=)
WO (1) WO2022271846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr

Also Published As

Publication number Publication date
WO2022271846A1 (en) 2022-12-29
JP2024523506A (ja) 2024-06-28
ES3042447T3 (en) 2025-11-20
EP4359400B1 (en) 2025-07-02
EP4359400A1 (en) 2024-05-01
IL309469A (en) 2024-02-01
US20240293404A1 (en) 2024-09-05
TW202317543A (zh) 2023-05-01
CN117836287A (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
US20240293404A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
WO2021218110A1 (zh) 一类苯并噻唑基联芳基类化合物、制备方法和用途
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
TWI555742B (zh) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, The use of medicine
BR112015020787B1 (pt) Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação
CN107540661A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
WO2022271630A1 (en) Egfr inhibitors
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
TWI780077B (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
JP2020526593A (ja) Ｎ−フェニル−２−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
US20240254130A1 (en) Salt and solid forms of a kinase inhibitor
CN104557870B (zh) 一种吡啶胺化合物的富马酸盐
WO2025051267A1 (zh) 一种lpar1拮抗剂及其用途
TWI824313B (zh) Ttk抑制劑之固體形式
WO2024042163A1 (en) Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
TWI862582B (zh) Plk4抑制劑之結晶型
CN118221669A (zh) 作为DNA聚合酶Theta抑制剂的衍生物
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
CN117836286A (zh) 用于治疗癌症的杂环egfr抑制剂
HK40104230A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
CN118221638B (zh) 作为DNA聚合酶Theta抑制剂的杂环化合物
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430